Kitov Pharmaceuticals (NASDAQ/TASE: KTOV) is an innovative biopharmaceutical company focused on late-stage drug development. Kitov’s pipeline currently features two combination drugs intended to treat osteoarthritis (OA) pain and hypertension (HTN) simultaneously. By lowering development risk and cost through streamlined regulatory approval of novel late-stage therapeutics, Kitov plans to delivers rapid ROI while making a meaningful impact on people’s lives.
Combination drug meets primary efficacy
endpoint in Phase III trial
Kitov’s KIT-302 is a combination drug that treats OA pain and HTN simultaneously. In December 2015, it was announced that the Phase III clinical trial for KIT-302 successfully met the primary efficacy endpoint of the trial protocol as approved by the U.S. Food & Drug Administration (FDA). Kitov plans to file a new drug application (NDA) for marketing approval of KIT-302 with the FDA by early 2017.
Leveraging deep regulatory
and clinical-trial expertise
Kitov features a world-caliber team with decades of managerial,
entrepreneurial, scientific, medical and financial experience. Chaired by a
former FDA medical officer, the Kitov team has a proven track record
leveraging deep regulatory and clinical-trial expertise that leads to
streamlined end-to-end drug development and approval.